{
    "clinical_study": {
        "@rank": "104309", 
        "arm_group": {
            "arm_group_label": "ALXN1101", 
            "arm_group_type": "Experimental", 
            "description": "daily IV infusions"
        }, 
        "brief_summary": {
            "textblock": "This study will include a screening period, a 6-month treatment period, and a 30-month,\n      long-term extension period."
        }, 
        "brief_title": "Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "MoCD Type A", 
            "Molybdenum Cofactor Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": "Metal Metabolism, Inborn Errors"
        }, 
        "detailed_description": {
            "textblock": "Patients will receive daily IV infusions of ALXN1101 starting on Day 1. After a prescribed\n      period, dosing will increase monthly based on defined patient safety measures.  After month\n      6, patients will continue daily dosing through month 36 at their last tolerated dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Male or female patients with a genetically confirmed diagnosis of MoCD Type A (MOCS1\n        mutation) and who are currently treated with rcPMP infusions.\n\n        Exclusion Criteria:\n\n        - Current or planned treatment with another investigational drug or device, with the\n        exception rcPMP treatment through Day -1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047461", 
            "org_study_id": "ALXN1101-MCD-201", 
            "secondary_id": "2013-002701-56"
        }, 
        "intervention": {
            "arm_group_label": "ALXN1101", 
            "description": "IV infusion", 
            "intervention_name": "ALXN1101", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Molybdenum"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Molybdenum cofactor deficiency (MoCD)", 
            "molybdenum cofactor (MoCo) biosynthesis", 
            "sulfite oxidase (SO)", 
            "xanthine dehydrogenase", 
            "aldehyde oxidase", 
            "S sulfocysteine (SSC)"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion International S\u00e0rl (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion International S\u00e0rl (sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "zip": "3168"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharma International Sarl (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "GZ Groningen", 
                        "country": "Netherlands", 
                        "zip": "9713"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion International S\u00e0rl (Sponsor)"
                }, 
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "zip": "G3 8SJ"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)", 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharma International S\u00e0rl (Sponsor)"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The type, number and frequency of adverse events and severity of adverse events (AEs) and serious adverse events (SAEs)\nChange from baseline in: clinical laboratory assessments, findings on  physical examination, vital sign measurements, and EEG results", 
            "measure": "Safety of ALXN1101", 
            "safety_issue": "Yes", 
            "time_frame": "First 6 months of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma concentration (Cmax), time to maximum observed plasma concentration (tmax), area under the plasma concentration-time curve (AUC), and terminal half-life (t\u00bd)", 
                "measure": "Pharmacokinetics parameters of ALXN1101", 
                "safety_issue": "No", 
                "time_frame": "First 6 months of treatment"
            }, 
            {
                "description": "Change from baseline in urine and blood biomarkers.", 
                "measure": "Effect of ALXN1101 on urine and blood biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Up to Month 36"
            }, 
            {
                "description": "Change from baseline on repeated Neurologic examinations such as tone, strengthen and reflexes.", 
                "measure": "Effect of ALXN1101 on neurologic function including motor examination", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Month 36"
            }, 
            {
                "description": "The type, number and frequency of adverse events and serious adverse events (SAEs)\nChange from baseline in: clinical laboratory assessments, findings on physical examination, vital sign measurements, and EEG results", 
                "measure": "Long-term safety of ALXN1101", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Month 36"
            }, 
            {
                "description": "Change from baseline in cognitive function using age appropriate measures of cognition, eg. Wechsler Preschoool and Primary Scale of intelligence", 
                "measure": "Effect of ALXN1101 on cognitive functions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Month 36"
            }
        ], 
        "source": "Alexion Pharma International Sarl", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharma International Sarl", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}